Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals

Antiviral Therapy

Volumn 21, Issue 5, 2016, Pages 447-453

  Nguyen, Linh Thuy ^a,b,c   Hall, Naomi ^c,d   Sheerin, Dylan ^c,e   Carr, Michael ^c   De Gascun, Cillian F ^c  

^a Ireland Vietnam Blood Borne Virus Initiative (IVVI)   (Ireland)

^b Ireland Vietnam Blood Borne Virus Initiative (IVVI)   (Viet Nam)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^e TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B; NONSTRUCTURAL PROTEIN 5B INHIBITOR; UNCLASSIFIED DRUG; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; FEMALE; GENETIC POLYMORPHISM; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HOMOZYGOTE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS MUTATION; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; MIDDLE AGED; MUTATION; PHYLOGENY; VIROLOGY; VIRUS GENE;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IRELAND; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; MUTATION; PHYLOGENY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84991465767     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3025     Document Type: Article

References (33)

1. Gogela NA, Lin MV, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep 2015; 12:68-78.
2. Collison M, Chin JL, Abu Shanab A, et al. Homozygosity for HLA group 2 alleles predicts treatment failure with interferonalpha and ribavirin in chronic hepatitis C virus genotype 1 infection. J Interferon Cytokine Res 2015; 35:126-133.
3. Nguyen LT, Gray E, Dean J, et al. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals. Antivir Ther 2015; 20:865-869.
4. Paolucci S, Fiorina L, Mariani B, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J 2013; 10:355.
5. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87:1544-1553.
6. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identiies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
7. Krishnan P, Beyer J, Mistry N, et al. In vitro and in vivo antiviral activity and resistance proile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 2015; 59:979-987.
8. Sun JH, O'Boyle Ii DR, Zhang Y, et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 2012; 55:1692-1699.
9. Peres-da-Silva A, de Almeida AJ, Lampe E. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatmentnaive patients infected with genotype 1 hepatitis C virus. J Antimicrob Chemother 2015; 70:726-730.
10. Plaza Z, Soriano V, Vispo E, et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther 2012; 17:921-926.
11. Kan T, Hashimoto S, Kawabe N, et al. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. J Gastroenterol 2016; 51:63-70.
12. Aissa Larousse J, Trimoulet P, Recordon Pinson P, et al. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia. Virol J 2015; 12:84.
13. Itakura J, Kurosaki M, Takada H, et al. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. Hepatol Res 2015; 45:E115-E121.
14. Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in the AVIATOR Study with paritaprevir/r, ombitasvir and dasabuvir in HCV genotype 1. Antimicrob Agents Chemother 2015; 59:5445-5454.
15. Peiffer KH, Sommer L, Susser S, et al. IFN lambda 4 genotypes and resistance-associated variants in HCV genotype 1 and 3 infected patients. Hepatology 2016; 63:63-73.
16. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81.
17. Pascu M, Martus P, Hohne M, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5AISDR: a meta-analysis focused on geographical differences. Gut 2004; 53:1345-1351.
18. Kohashi T, Maekawa S, Sakamoto N, et al. Site-speciic mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat 2006; 13:582-590.
19. Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate eficiently in cultured Huh7 cells. J Virol 2002; 76:2997-3006.
20. Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, et al. Contribution of insertions and deletions to the variability of hepatitis C virus populations. J Gen Virol 2007; 88:2198-2203.
21. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res 2014; 105:64-71.
22. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to directacting antiviral agents. Antiviral Res 2014; 108:181-191.
23. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015; 61:56-65.
24. Tong X, Le Pogam S, Li L, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 2014; 209:668-675.
25. Kinugasa H, Ikeda F, Takaguchi K, et al. Low frequency of drug-resistant virus did not affect the therapeutic eficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype 1 infection. Antivir Ther 2016; 21:37-44.
26. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58:646-654.
27. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54:1924-1935.
28. Wang C, Sun JH, O'Boyle DR, II, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 2013; 57:2054-2065.
29. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54:3641-3650.
30. Lawitz EJ, Gruener D, Hill JM, et al. A Phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57:24-31.
31. Bilello JP, Lallos LB, McCarville JF, et al. In vitro activity and resistance proile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2014; 58:4431-4442.
32. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype proiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56:3359-3368.
33. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34 Suppl 1:69-78.